Phase 3
N=105
Analgesic Effect of Peripheral Dexmedetomidine
Third Molar Extraction
Bottom Line
View on ClinicalTrials.gov: NCT00971178 ↗Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Pain Score at Rest — 165.5; 218.2; 233.8 score on a scale×hr
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- local dexmedetomidine (Drug); Peripheral normal saline (Drug); IV dexmedetomidine (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- The University of Hong Kong
- Primary completion
- Mar 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Pain Score at Rest |
165.5; 218.2; 233.8 | — |
Summary
Dexmedetomidine is an alpha 2-adrenoreceptor agonist, which provides sedation, analgesia and anxiolysis in clinical practice (Cortinez et al., 2004,Hall et al., 2000). Three types of alpha 2-adrenergic receptor subtypes are found in the human body and they have been designated alpha 2A, alpha 2B and alpha 2C. The alpha 2A subtype is most likely responsible for the analgesic properties of dexmedetomidine in both peripheral and central sites (Kingery et al., 2000, Smith et al., 2001). Activation of central alpha 2-adrenoreceptors in the locus ceruleus (Correa-Sales et al., 1992) and the dorsal horn of the spinal cord (Gaumann et al., 1992b) are responsible for both analgesic and sedative effects. Dexmedetomidine has a very high alpha 2 to alpha 1 selectivity, 1620 to 1, or approximately 8 times that of clonidine. It is also 4 to 6 times more potent than clonidine by weight (Bhana et al., 2000).
Although dexmedetomidine produces dose dependent sedation upon intravenous administration, its the analgesic effect is of dexmedetomidine is more variable and controversial. In an ischaemic pain model in healthy volunteers, a single bolus of dexmedetomidine produced a 50% reduction in pain scores when compared to placebo (Jaakola et al., 1991). In another volunteer study using the cold pressor test, dexmedetomidine 1 µg/kg over 10 minutes followed by an infusion of 0.2 to 0.6 µg/kg/hour reduced pain by approximately 30% (Hall et al., 2000). However, when administered as a target controlled infusion at concentrations ranging from 0.09 to 1.23 ng/mL, dexmedetomidine had no analgesic effect in human volunteers subjected to heat and electrical pain, although sedation was produced (Memis et al., 2004).
Clonidine and dexmedetomidine are two common alpha 2 agonists used clinically. Although clonidine former has been used successfully in regional analgesia and anesthesia (Gabriel et al., 2001)., There are only very few studies evaluating the peripheral analgesic effects of dexmedetomidine. Since acute postoperative dental pain is a common analgesia model (Cooper, 1991; US Food and Drug Administration 1992), the investigators conducted this study, aiming to assess the postoperative analgesic efficacy of peripheral dexmedetomidine after bilateral third molar surgery under general anaesthesia. The analgesic effects were compared up to the 72nd hour postoperatively in order to evaluate any potential preventive analgesic effect.
Eligibility Criteria
Inclusion Criteria
- American Society of Anesthesiologists (ASA) physical status I and II
- Age between 18 and 50 years of age with 4 bilateral impacted third molar teeth scheduled for extraction under general anaesthesia
Exclusion criteria
- Clinical history or electrocardiographic evidence of heart block
- Ischaemic heart disease
- Asthma
- Sleep apnoea syndrome
- Impaired liver or renal function
- Alcohol consumption in excess of 28 units per week
- Pregnancy
- Patient refusal
- Known psychiatric illness
- Chronic sedative or analgesic use, and regular use of or known allergy to dexmedetomidine, paracetamol or dextropropoxypheneopioids
- Patients with preoperative inflammation at the site of surgery were also excluded
Data sourced from ClinicalTrials.gov (NCT00971178). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.